Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02927301 · ClinicalTrials.gov registry record · Phase 2
A Study of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Resectable Non-Small Cell Lung Cancer (NSCLC) - Lung Cancer Mutation Consortium (LCMC3)
A Phase 2 study, sponsored by Genentech.
- Completed
- Registry status
- Phase 2
- Development phase
- 181
- Enrollment target
NCT02927301 is a Phase 2 study that has completed, run by Genentech. The registered enrollment target is 181 participants.
The verdict
NCT02927301, a Phase 2 study, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 181 participants
- Enrollment target
Study Summary
This study was designed to evaluate the safety and efficacy of neoadjuvant and adjuvant atezolizumab in participants with resectable Non-Small Cell Lung Cancer (NSCLC). Neoadjuvant therapy consisted of two 21-day cycles with atezolizumab. Following surgery, adjuvant therapy consisted of up to 12 months of atezolizumab in participants who demonstrate clinical benefit with neoadjuvant therapy. All participants who undergo surgery entered a surveillance period, which consisted of standardized blood sample collection and Chest CT Scans, for up to 2 years. All participants were monitored for disease recurrence and survival for up to 3 years after last dose of study drug.
Interventions
- DRUG Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 181 participants |
| Start Date | 2017-04-20 |
| Est. Completion | 2023-09-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02927301
The ClinicalTrials.gov registry entry for NCT02927301 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 181 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody is the first listed.
NCT02927301 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02927301 about?
NCT02927301 is a clinical study titled "A Study of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Resectable Non-Small Cell Lung Cancer (NSCLC) - Lung Cancer Mutation Consortium (LCMC3)". This study was designed to evaluate the safety and efficacy of neoadjuvant and adjuvant atezolizumab in participants with resectable Non-Small Cell Lung Cancer (NSCLC). Neoadjuvant therapy consisted of two 21-day cycles with atezolizumab. Following surgery, adjuvant therapy consisted of up to 12 mon...
What is the current status of trial NCT02927301?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 181 participants. The study started on 2017-04-20. Estimated completion is 2023-09-05.
What interventions are being tested in trial NCT02927301?
The interventions under investigation include: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody (DRUG).
Who is sponsoring clinical trial NCT02927301?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.